Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement

Apr

22

Today In Oncology

Metastatic NSCLC Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy

High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity

Methylation-Based AI Model Classifies Tumors of Unknown Origin

Initial Data Shows Safety for WEE1 PKMYT1 Inhibitor Combination in Advanced Solid Tumors

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Advertisement

© 2026 HSP News Service, L.L.C.